Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

Phase 4 Completed 24 enrolled Montefiore Medical Center Ortho-McNeil Pharmaceutical · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ages 18-65).

Timeline

Start: 2004-08
Primary completion: —
Completion: 2006-08

Outcome

Mixed primary results

paper significant treatment effect on the YBOCS compulsions (P = .014) subscale, but not the obsessions (P = .99) subscale or the total score (P = .11). PMID 20816027 ↗

paper the topiramate group (mean endpoint dose = 177.8 ± 134.2 mg/d; range, 50-400 mg/d) showed an average linear decrease of 5.38 points on the compulsions subscale compared to 0.6 points in the placebo group. PMID 20816027 ↗

Publications

Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 May;72(5):716-21. doi: 10.4088/JCP.09m05266gre. Epub 2010 Aug 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topiramate	Small molecule	—	—